Drug Trial Radar · NCT05277571
A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)
Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
109
Actual
Start
Mar 7, 2022
Primary completion
Jul 17, 2025
Study completion Sep 19, 2025
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Mar 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB1381 (intravenous and subcutaneous) in healthy study participants and after repeat intravenous dosing in study participants with atopic dermatitis. Efficacy will be assessed following repeat intravenous dosing versus placebo in study participants with atopic dermatitis.
Conditions
- Atopic Dermatitis
Interventions
UCB1381Biological
UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B
PlaceboDrug
Placebo will be administered iv or sc in Part A and iv in Part B to maintain the blinding.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidents of treatment-emergent adverse events (TEAEs) from Baseline through the End of Study (EOS) Visit (Week 12) in Part ATime frame: From Baseline up to Week 12 in Part A
- Incidents of treatment-emergent serious adverse events (TESAEs) from Baseline through the EOS Visit (Week 12) in Part ATime frame: From Baseline up to Week 12 in Part A
- Incidents of TEAEs from Baseline through the EOS Visit (Week 22) in Part BTime frame: From Baseline up to Week 22 in Part B
- Incidents of TESAEs from Baseline through the EOS Visit (Week 22) in Part BTime frame: From Baseline up to Week 22 in Part B
- ≥75% improvement vs Baseline (Yes/No) in Eczema Area and Severity Index score (EASI75) at Week 12 in Part BTime frame: From Baseline up to Week 12 in Part B
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Up0110 125
Beverly Hills, California
Up0110 101
Glendale, California
Up0110 116
Los Angeles, California
Up0110 121
Northridge, California
Up0110 126
Tustin, California
Up0110 127
Valencia, California
Up0110 108
Clearwater, Florida
Up0110 109
Miami Lakes, Florida
Up0110 106
Ocala, Florida
Up0110 102
St. Petersburg, Florida
Up0110 111
College Park, Georgia
Up0110 114
Minneapolis, Minnesota
Up0110 107
New York, New York
Up0110 124
Winston-Salem, North Carolina
Up0110 104
Oklahoma City, Oklahoma
Up0110 119
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.